Abstract
In many cases, an appropriate vasodilator alone will relieve symptoms and improve quality of life; in others, an inotropic agent must be added. Careful selection of both patient and specific agent is essential, as is monitoring for side effects. Clinical guidelines are described in the context of the known role of elevated arterial input impedance in the symptomatology of heart failure.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 37-52 |
| Number of pages | 16 |
| Journal | Hospital practice |
| Volume | 19 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1984 |